L. A. Mineeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
L. A. Mineeva has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrey A. Baranov
Yaroslavl State Medical University
2 shared publications - Natalia A. Lapkina
Yaroslavl State Medical University
2 shared publications - A. A. Kolinyko
Yaroslavl State Medical University
1 shared publication - Alexander S. Artyuhov
N.I. Pirogov Russian National Research Medical University
1 shared publication - D. D. Adamov
Yaroslavl State Medical University
1 shared publication - Evgenii L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; N.I. Pirogov Russian National Research Medical University
1 shared publication
Latest Publications
- Open Access
- 3 February 2025
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 2 (4) , 82-93
Erythrocytic indices of clinical blood analysis and reference intervals among men and women aged 18–45 years
Relevance. The determination of reference intervals (RI) in clinical blood analysis for erythrocytes and their specific parameters: mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and red cell distribution width (RDW), allows us to use these parameters for differential diagnostics of various pathological conditions from variants of norm.Objective. Calculate the RI for erythrocyte parameters of a complete blood count for patients in a certain age group (18– 45 years) with normal indicators of iron homeostasis. The reference ranges may vary depending on the analytical systems and diagnostic reagents used.Material and methods. The study included blood samples from 158 healthy volunteers aged 18–45 years, of whom 127 (80.4 %) were women and 31 (19.6 %) were men. The data were obtained from the «KDL-TEST» company database for the period from 01.01.2023 to 01.01.2024. The criteria for inclusion in the study were: age from 18 to 45 years, clinical blood test results, and iron homeostasis within the RI of the «KDL-TEST» laboratory, absence of signs of an inflammatory process based on normal levels of C-reactive protein (CRP). Analyses were performed using a hematological analyzer Mindray BC- 6800 (manufactured by Mindray, China) and an automatic biochemical analyzer model AU-5800 (Beckman Coulter, USA) using IRON reagents (Beckman Coulter, USA) for the photometric colorimetric method and CRP-latex (Beckman Coulter, USA) immunoturbidimetric method.Results. The studies revealed a decrease in the upper limit of the RI for red blood cells (RBC) and their indices (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in women compared with the RI of the Russian National Standard (2009), which amounted to 4 % for the number of red blood cells, 5 % for hemoglobin, 2 % for hematocrit, 3.8 % for MCV and 3.5 % for MCH, as well as 4.2 % for MCHC; and a decrease in the upper limit of the RI of erythrocytes and erythrocyte indices (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in relation to the RI of the Russian National Standard (2009) in men for erythrocytes by 3.9 %, hemoglobin by 4, 6 %, MCV — by 1.9 %, MCH — by 4 %, MCHC — by 5.8 %. No significant differences were found in the values of erythrocytes and their specific parameters, hemoglobin, and hematocrit, between the data of the hematology analyzers Mindray BC-6800 and Sysmex XE series (p >0.05).Conclusions. A decrease in the RI of clinical blood analysis in women and men for some hemogram parameters (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in comparison with the RI of clinical blood analysis of the Russian National Standard (2009), which are within the generally accepted statistically acceptable deviations, was found. The use of automated hematology analyzers did not significantly affect the RI of erythrocytes or their specific parameters.
- 3 February 2025
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 2 (4) , 82-93
Open AccessErythrocytic indices of clinical blood analysis and reference intervals among men and women aged 18–45 years
Relevance. The determination of reference intervals (RI) in clinical blood analysis for erythrocytes and their specific parameters: mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and red cell distribution width (RDW), allows us to use these parameters for differential diagnostics of various pathological conditions from variants of norm.Objective. Calculate the RI for erythrocyte parameters of a complete blood count for patients in a certain age group (18– 45 years) with normal indicators of iron homeostasis. The reference ranges may vary depending on the analytical systems and diagnostic reagents used.Material and methods. The study included blood samples from 158 healthy volunteers aged 18–45 years, of whom 127 (80.4 %) were women and 31 (19.6 %) were men. The data were obtained from the «KDL-TEST» company database for the period from 01.01.2023 to 01.01.2024. The criteria for inclusion in the study were: age from 18 to 45 years, clinical blood test results, and iron homeostasis within the RI of the «KDL-TEST» laboratory, absence of signs of an inflammatory process based on normal levels of C-reactive protein (CRP). Analyses were performed using a hematological analyzer Mindray BC- 6800 (manufactured by Mindray, China) and an automatic biochemical analyzer model AU-5800 (Beckman Coulter, USA) using IRON reagents (Beckman Coulter, USA) for the photometric colorimetric method and CRP-latex (Beckman Coulter, USA) immunoturbidimetric method.Results. The studies revealed a decrease in the upper limit of the RI for red blood cells (RBC) and their indices (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in women compared with the RI of the Russian National Standard (2009), which amounted to 4 % for the number of red blood cells, 5 % for hemoglobin, 2 % for hematocrit, 3.8 % for MCV and 3.5 % for MCH, as well as 4.2 % for MCHC; and a decrease in the upper limit of the RI of erythrocytes and erythrocyte indices (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in relation to the RI of the Russian National Standard (2009) in men for erythrocytes by 3.9 %, hemoglobin by 4, 6 %, MCV — by 1.9 %, MCH — by 4 %, MCHC — by 5.8 %. No significant differences were found in the values of erythrocytes and their specific parameters, hemoglobin, and hematocrit, between the data of the hematology analyzers Mindray BC-6800 and Sysmex XE series (p >0.05).Conclusions. A decrease in the RI of clinical blood analysis in women and men for some hemogram parameters (RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV) in comparison with the RI of clinical blood analysis of the Russian National Standard (2009), which are within the generally accepted statistically acceptable deviations, was found. The use of automated hematology analyzers did not significantly affect the RI of erythrocytes or their specific parameters.
- Open Access
- 31 August 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (4) , 475-484
Dynamics of clinical manifestations and cytokine concentrations in patients with rheumatoid arthritis on olokizumab therapy
The aim of the study was to investigate the dynamics of clinical and laboratory parameters of inflammatory disease activity and cytokines in patients with rheumatoid arthritis (RA) against the background of olokizumab (OKZ) treatment.Materials and methods. Ten patients with a reliable diagnosis of RA were examined: patients’ age was 46.00 (30.00; 60.00) years, duration of disease was 9.0 (3.0; 12,0) years. All patients had moderate to high disease activity: DAS28-ESR (Disease Activity Score 28 with Erythrocyte Sedimentation Rate) – 513 (4.34; 5,80); CDAI (Clinical Disease Activity Index) – 30.00 (24.00; 35.00); SDAI (Simplified Disease Activity Index) – 31.86 (24.36; 38.59). All patients were treated with OKZ at a dose of 64 mg subcutaneously every 4 weeks on the background of therapy with methotrexate, leflunomide, nonsteroidal anti-inflammatory drugs, and glucocorticoids. Observations were performed before treatment and after 3, 6 months of therapy. Serum levels of 15 cytokines: interleukin (IL) 1β, IL-4, IL-6, tumor necrosis factor α (TNF-α), interferon (INF) γ, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, sCD40L, – were examined using multiplex xMAR technology.Results. After 3 and 6 months of OKZ therapy, there was a significant decrease in DAS28-ESR of 3.53 (2.83; 4.26) and 3.48 (2.8; 4.10); CDAI – 11.00 (6.0; 16.00) and 10.0 (5.0; 15.0); SDAI – 10.0 (5.0; 15.0) and 10.17 (7.02; 15.02); C-reactive protein (CRP) concentrations (initial – 14.30 (7.00; 24.70) mg/l, after 3 months – 0.70 (0.40; 0.90) mg/l and after 6 months – 0.65 (0.20; 3.00) mg/l). After 3 months of treatment we found an increase in IL-6 concentration (initial – 1.89 (1.61; 2.33) pg/ml and 89.98 (35.09; 165.84) pg/ml; pConclusion. The use of OKZ leads to an increase in the concentration of total IL-6 in the blood serum of RA patients, while the clinical and laboratory activity of the disease decreases.
- 31 August 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (4) , 475-484
Open AccessDynamics of clinical manifestations and cytokine concentrations in patients with rheumatoid arthritis on olokizumab therapy
The aim of the study was to investigate the dynamics of clinical and laboratory parameters of inflammatory disease activity and cytokines in patients with rheumatoid arthritis (RA) against the background of olokizumab (OKZ) treatment.Materials and methods. Ten patients with a reliable diagnosis of RA were examined: patients’ age was 46.00 (30.00; 60.00) years, duration of disease was 9.0 (3.0; 12,0) years. All patients had moderate to high disease activity: DAS28-ESR (Disease Activity Score 28 with Erythrocyte Sedimentation Rate) – 513 (4.34; 5,80); CDAI (Clinical Disease Activity Index) – 30.00 (24.00; 35.00); SDAI (Simplified Disease Activity Index) – 31.86 (24.36; 38.59). All patients were treated with OKZ at a dose of 64 mg subcutaneously every 4 weeks on the background of therapy with methotrexate, leflunomide, nonsteroidal anti-inflammatory drugs, and glucocorticoids. Observations were performed before treatment and after 3, 6 months of therapy. Serum levels of 15 cytokines: interleukin (IL) 1β, IL-4, IL-6, tumor necrosis factor α (TNF-α), interferon (INF) γ, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, sCD40L, – were examined using multiplex xMAR technology.Results. After 3 and 6 months of OKZ therapy, there was a significant decrease in DAS28-ESR of 3.53 (2.83; 4.26) and 3.48 (2.8; 4.10); CDAI – 11.00 (6.0; 16.00) and 10.0 (5.0; 15.0); SDAI – 10.0 (5.0; 15.0) and 10.17 (7.02; 15.02); C-reactive protein (CRP) concentrations (initial – 14.30 (7.00; 24.70) mg/l, after 3 months – 0.70 (0.40; 0.90) mg/l and after 6 months – 0.65 (0.20; 3.00) mg/l). After 3 months of treatment we found an increase in IL-6 concentration (initial – 1.89 (1.61; 2.33) pg/ml and 89.98 (35.09; 165.84) pg/ml; pConclusion. The use of OKZ leads to an increase in the concentration of total IL-6 in the blood serum of RA patients, while the clinical and laboratory activity of the disease decreases.